Provided by Tiger Fintech (Singapore) Pte. Ltd.

Beam Therapeutics, Inc.

17.53
+0.52003.06%
Post-market: 17.42-0.1100-0.63%17:35 EDT
Volume:1.58M
Turnover:27.72M
Market Cap:1.76B
PE:-3.83
High:18.23
Open:16.85
Low:16.59
Close:17.01
Loading ...

Beam Therapeutics (BEAM) Gets a Buy from Wedbush

TIPRANKS
·
16 Jun

Analysts Have Conflicting Sentiments on These Healthcare Companies: Merus (MRUS) and Beam Therapeutics (BEAM)

TIPRANKS
·
16 Jun

Beam Therapeutics’ BEAM-101: Promising Advancements in Sickle Cell Disease Treatment with Strong Phase 1/2 Trial Results

TIPRANKS
·
13 Jun

Beam Therapeutics Announces Promising New Data from BEACON Phase 1/2 Trial of BEAM-101 for Sickle Cell Disease at EHA 2025 Congress

Reuters
·
13 Jun

Beam Therapeutics Inc - Enrollment Complete in Beacon Trial, 30 Patients Expected by Mid-2025

THOMSON REUTERS
·
13 Jun

Beam Therapeutics Announces New Data From Beacon Phase 1/2 Clinical Trial of Beam-101 Supporting Differentiated Profile in Sickle Cell Disease (Scd) at European Hematology Association (Eha) 2025 Congress

THOMSON REUTERS
·
13 Jun

Beam Therapeutics Confirms Key Decisions at Annual Meeting

TIPRANKS
·
07 Jun

Bernstein Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)

TIPRANKS
·
06 Jun

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

Zacks
·
04 Jun

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?

Zacks
·
04 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, Hewlett Packard Enterprise, Venture Global

Reuters
·
04 Jun

Roadzen’s DrivebuddyAI Awarded Patent for Real-Time Driver Drowsiness Detection — Crosses 1.8 Billion Kilometers of Real-World AI Driving Data

GlobeNewswire
·
03 Jun

Beam Therapeutics Inc. Receives FDA Orphan Drug Designation for BEAM-101 in Sickle Cell Disease Treatment

Reuters
·
03 Jun

Beam Therapeutics Inc - Beam-101 Safety Profile Consistent With Busulfan Conditioning

THOMSON REUTERS
·
03 Jun

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to Beam-101 for the Treatment of Sickle Cell Disease

THOMSON REUTERS
·
03 Jun

Beam Therapeutics treatment of sickle cell disease granted orphan designation

TIPRANKS
·
31 May

Sector Update: Health Care Stocks Fall Pre-Bell Friday

MT Newswires Live
·
30 May

Beam Therapeutics Says FDA Grants Orphan Drug Designation to Lung, Liver Treatment

Dow Jones
·
30 May

Beam Therapeutics receives orphan drug designation for BEAM-302

TIPRANKS
·
30 May

Beam Therapeutics Inc - Initiates Dosing in Fourth Cohort, Data Expected in H2 2025

THOMSON REUTERS
·
30 May